Protara Therapeutics, Inc. (NASDAQ: TARA) reported Q2 EPS of ($0.36), $0.02 worse than the analyst estimate of ($0.34).

For earnings history and earnings-related data on Protara Therapeutics, Inc. (TARA) click here.